而他认为我们现在只能获得关于局部器官耐受性和剂量限制的数据。
But he suggested that what could be obtained now are data about partial organ tolerance and dose constraints.
结论：常规治疗联合厄贝沙坦治疗慢性心衰，可进一步获得有益的疗效，并且有良好的安全性及耐受性。
Conclusion: Irbesartan combined with conventional treatment of chronic heart failure has further beneficial effect, and has a good safety and tolerability.
结论：常规治疗联合厄贝沙坦治疗慢性心衰，可进一步获得有益的疗效，并且有良好的安全性及耐受性。
Conclusion: Irbesartan combined with conventional treatment of chronic heart failure has further beneficial effect, and has a good safety and tolerability.
应用推荐